Track market-moving stories before they get noisy

Posted by Defense World Staff on Apr 24th, 2026

Cwm LLC increased its holdings in shares of SiteOne Landscape Supply, Inc. (NYSE:SITE – Free Report) by 197.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,038 shares of the industrial products company’s stock after purchasing an additional 13,971 shares during the quarter. Cwm LLC’s holdings in SiteOne Landscape Supply were worth $2,620,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of SiteOne Landscape Supply during the third quarter valued at $1,932,000. Magnetar Financial LLC lifted its holdings in shares of SiteOne Landscape Supply by 41.0% during the third quarter. Magnetar Financial LLC now owns 46,669 shares of the industrial products company’s stock valued at $6,011,000 after purchasing an additional 13,572 shares in the last quarter. Interval Partners LP bought a new position in shares of SiteOne Landscape Supply during the third quarter valued at $12,720,000. 59 North Capital Management LP bought a new position in shares of SiteOne Landscape Supply during the third quarter valued at $214,417,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of SiteOne Landscape Supply by 19.9% during the third quarter. New York State Common Retirement Fund now owns 104,493 shares of the industrial products company’s stock valued at $13,459,000 after purchasing an additional 17,362 shares in the last quarter.

SiteOne Landscape Supply Stock Up 0.7% SITE stock opened at $144.46 on Friday. SiteOne Landscape Supply, Inc. has a fifty-two week low of $108.11 and a fifty-two week high of $168.56. The business’s 50-day moving average is $138.06 and its two-hundred day moving average is $134.37. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.20 and a current ratio of 2.47. The company has a market cap of $6.40 billion, a price-to-earnings ratio of 42.99, a P/E/G ratio of 1.78 and a beta of 1.57.

SiteOne Landscape Supply (NYSE:SITE – Get Free Report) last posted its earnings results on Wednesday, February 11th. The industrial products company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. SiteOne Landscape Supply had a return on equity of 9.28% and a net margin of 3.23%.SiteOne Landscape Supply’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.48) earnings per share. As a group, analysts forecast that SiteOne Landscape Supply, Inc. will post 4.31 earnings per share for the current year.

Analyst Ratings Changes A number of research analysts have weighed in on the company. Zacks Research raised SiteOne Landscape Supply from a “strong sell” rating to a “hold” rating in a report on Friday, February 13th. Robert W. Baird set a $190.00 target price on SiteOne Landscape Supply in a report on Thursday, February 12th. Stifel Nicolaus set a $144.00 target price on SiteOne Landscape Supply in a report on Monday, February 9th. Truist Financial increased their target price on SiteOne Landscape Supply from $165.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of SiteOne Landscape Supply in a report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, SiteOne Landscape Supply currently has a consensus rating of “Hold” and an average target price of $162.22.

Get Our Latest Stock Report on SiteOne Landscape Supply

Insider Buying and Selling In other SiteOne Landscape Supply news, EVP Eric J. Elema sold 1,765 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $158.01, for a total value of $278,887.65. Following the completion of the sale, the executive vice president owned 2,911 shares in the company, valued at $459,967.11. This represents a 37.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 2.10% of the stock is currently owned by insiders.

About SiteOne Landscape Supply (Free Report)

SiteOne Landscape Supply is a leading distributor of landscape supplies and irrigation equipment in North America. The company serves a broad range of customers, including independent landscapers, lawn and garden retailers, municipalities and other commercial landscape professionals. Its product portfolio spans irrigation and lighting controls, pipes and fittings, fertilizers and soils, lighting fixtures, hardscapes, outdoor lighting systems and related installation accessories.

In addition to core product lines, SiteOne offers agronomic services designed to optimize turf and plant health, as well as online tools and training resources to help customers plan, specify and manage projects more efficiently.

See Also Five stocks we like better than SiteOne Landscape Supply Want to see what other hedge funds are holding SITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SiteOne Landscape Supply, Inc. (NYSE:SITE – Free Report).

Receive News & Ratings for SiteOne Landscape Supply Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiteOne Landscape Supply and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECwm LLC Has $2.70 Million Holdings in Darden Restaurants, Inc. $DRI

NEXT HEADLINE »Cwm LLC Buys 24,139 Shares of Essent Group Ltd. $ESNT

SiteOne Landscape (SITE - Free Report) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.2, delivering a surprise of +31.03%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

SiteOne Landscape, which belongs to the Zacks Industrial Services industry, posted revenues of $940.1 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 5.18%. This compares to year-ago revenues of $939.4 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

SiteOne Landscape shares have added about 14.8% since the beginning of the year versus the S&P 500's gain of 4.3%.

What's Next for SiteOne Landscape?While SiteOne Landscape has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for SiteOne Landscape was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.33 on $1.54 billion in revenues for the coming quarter and $4.43 on $4.94 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Industrial Services is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, W.W. Grainger (GWW - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This seller of maintenance and other supplies is expected to post quarterly earnings of $10.20 per share in its upcoming report, which represents a year-over-year change of +3.5%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level.

W.W. Grainger's revenues are expected to be $4.57 billion, up 6.1% from the year-ago quarter.

NERD RETURNS TO PROFITABILITY AND CONTINUED REVENUE MOMENTUM

Nerds On Site Inc. (CSE: NERD) (OTC: NOSUF)

, /PRNewswire/ - Nerds On Site Inc. ("NOS" or the "Company") (CSE: NERD), a leading managed IT and cybersecurity services provider serving small and medium-sized enterprises across Canada and the United States, today announced its financial results for the three and nine months ended February 28, 2026.

The Company delivered continued revenue growth, improved margins, and a return to quarterly profitability, reflecting disciplined execution, a strengthening recurring revenue base, and ongoing demand for cybersecurity and managed IT services.

Q3 FY2026 Financial Highlights

For the three months ended February 28, 2026:

Revenue increased to $3,284,428, up 9% from $3,004,549 in the prior year period Gross profit rose to $861,370, with gross margin improving to 26% (from 23%) SG&A expenses declined 16%, improving to 23% of revenue (from 30%) Net income reached $51,877, compared to a net loss of $198,156 last year Earnings per share improved to $0.0006, compared to a loss of $0.0022 For the nine months ended February 28, 2026:

Revenue increased to $10,077,870, up 18% year-over-year Gross profit rose to $2,526,147, with stable margins of 25% SG&A expenses decreased 7%, improving to 25% of revenue (from 32%) Net loss reduced significantly to $280,840, compared to $559,211 in the prior year Operating cash usage improved dramatically to $104,135, versus $693,709 in the prior period These results highlight meaningful operational progress and improved financial discipline across the organization.

Return to Profitability Marks Key Inflection Point

The Company's return to quarterly net profitability represents a critical milestone in its evolution.

This improvement was driven by:

Growth in recurring revenue from business clients in Canada Enhanced cost management and operational efficiency A more favorable product mix and improved sourcing strategies Continued leverage from the Company's scalable service model Management views this quarter as an important step toward sustained profitability.

Recurring Revenue Model Driving Stability and Growth

Nerds On Site continues to benefit from its high-visibility recurring revenue model, which is foundational to its business strategy.

During the nine-month period:

Business recurring revenue in Canada increased by 17% The Company served over 10,000 customers annually, with 130,000+ clients served since inception Recurring service agreements continue to provide predictable cash flow and long-term client relationships This model positions the Company to generate consistent revenue while scaling efficiently across markets.

Operational Efficiency and Margin Expansion

The Company achieved significant improvements in cost structure, with SG&A reductions driven by:

Lower payroll and operational costs within NOS Technical Services Timing efficiencies in business development spending Continued optimization of internal systems and processes Gross margin expansion to 26% in the quarter reflects:

Improved pricing from suppliers Strategic sourcing initiatives Increased contribution from higher-margin service revenues These improvements demonstrate the Company's ability to scale profitably while maintaining service quality.

CEO Charlie Regan commented:
"Our return to profitability this quarter is a defining moment for Nerds On Site. We've spent decades humanizing technology, and today we're scaling that vision across Canada and deeper into USA. This quarter's profitability is not the destination— Nerds On Site is transitioning from a growth story into a performance story. Our platform, our people, and our model are designed for a world where trust, speed, and security are everything. We believe we are still in the early innings of a very large market opportunity to deliver long-term value to our Clients and shareholders."

Market Position and Industry Tailwinds

Management believes the Company is well positioned within a rapidly evolving IT landscape:

Increasing cybersecurity threats are driving demand for managed services The shift to hybrid and remote work environments continues to accelerate IT complexity SMEs are increasingly outsourcing IT to trusted managed service providers Nerds On Site's combination of:

A distributed "eNerd" contractor network More than 100,950 Verified 5-Star Client reviews  A strong recurring revenue base provides a scalable and differentiated operating model. Outlook

Looking ahead, Nerds On Site is focused on:

Driving sustained profitability through operational leverage Expanding recurring revenue streams Growing its presence in the United States market Strengthening its position in cybersecurity and managed services Management believes that the Company's improving financial performance, combined with strong industry demand, positions it well for continued growth and value creation.

About Nerds On Site Inc.
Nerds On Site Inc. is a managed IT and cybersecurity service provider delivering technology solutions to small and medium-sized enterprises across Canada and the United States. The Company operates a network of highly skilled IT professionals ("eNerds") supported by its proprietary ERP platform, enabling scalable, efficient, and customer-focused service delivery.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements.

Charles Regan
NERDS ON SITE INC
+1 519-639-4382
Email us here

SOURCE Nerds On Site Inc.

On April 29, 2026, SiteOne Landscape Supply Inc SITE shares fell 15.4% today, closing at $120.97. This decline comes amid a 52-week trading range of $108.12 to $168.56, highlighting significant volatility in the stock's performance.

GF Value™ verdict: Current price of $120.97 is 22.8% below the GF Value™ estimate of $156.73.GF Score™ of 89/100 indicates a strong overall assessment based on various financial metrics.Notable signal: Insider activity shows that insiders sold $0.3 million worth of shares in the last three months, with no buying reported. Is SITE Overvalued or Undervalued? The current price of SiteOne Landscape Supply Inc at $120.97 is significantly undervalued according to GF Value™, which estimates the fair value at $156.73. This represents a margin of safety of 22.8%, suggesting that the stock may offer an attractive opportunity for long-term investors. The GF Valuation label of "Modestly Undervalued" reinforces this perspective, indicating that while the stock is not drastically undervalued, there exists a favorable discrepancy between its market price and intrinsic value.

Investing in stocks that are undervalued can provide a cushion against potential market downturns, as the intrinsic value serves as a benchmark for future performance. However, investors should remain cautious of market conditions and any factors that could influence the company's financial health moving forward. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

How Does SITE's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 35.9x 41.7x Forward P/E 27.7x N/A The current P/E ratio of 35.9x is notably lower than the 5-year median P/E of 41.7x, indicating that the stock is trading below its historical valuation levels. The forward P/E of 27.7x further suggests that the stock may continue to be seen as undervalued, aligning with the GF Value™ verdict that the stock is modestly undervalued.

What Does SITE's GF Score™ Tell Us? Metric Rating GF Score™ 89 Financial Strength 7/10 Profitability 8/10 Growth 7/10 Valuation 10/10 Momentum 8/10 The GF Score™ of 89/100 reflects a strong overall assessment of SiteOne Landscape Supply Inc, with particularly high ratings in Valuation (10/10) and Profitability (8/10). These scores suggest that the company is financially solid and profitable, contributing to its strong investment profile. However, the Financial Strength score of 7/10 indicates that while the company is stable, there may be areas for improvement in terms of financial resilience.

What Are Insiders Doing with SITE Stock? In the past three months, insiders have sold $0.3 million worth of shares, with no reported buying activity. This selling pattern could suggest a lack of confidence from insiders about the stock's short-term prospects, which may impact investor sentiment. However, it is essential to interpret insider activity within the broader context of market conditions and company performance.

What This Means for Investors Based on the GF Value™ assessment, SiteOne Landscape Supply Inc is currently undervalued, presenting a potential opportunity for long-term investors. However, the recent insider selling activity and market volatility should be considered when evaluating this investment opportunity.

For the complete analysis, visit the SiteOne Landscape Supply Inc SITE stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is SITE's GF Score™?

SITE's GF Score™ is 89/100, indicating a strong overall assessment that suggests the stock may generate higher long-term returns based on various financial metrics.

Is SITE overvalued or undervalued?

According to GF Value™, SITE is currently undervalued, with a price of $120.97 being 22.8% below its estimated fair value of $156.73.

What is SITE's P/E ratio?

SITE's P/E (TTM) ratio is 35.9x, which is 14% below its 5-year median P/E of 41.7x, indicating that the stock is trading below its historical valuation levels.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Meadowmont Crossing.

© welcomia / iStock via Getty Images

When SiteOne Landscape Supply (NYSE: SITE | SITE Price Prediction) hit public markets on May 12, 2016, it was a niche bet: the only national wholesale distributor in a deeply fragmented landscape supply industry. A decade later, that thesis has played out. SiteOne has rolled up local players at a relentless pace—completing eight acquisitions in fiscal 2025 alone—including Reinders, Bourget Flagstone, Red’s Home & Garden, and a string of regional nurseries.

CEO Doug Black has paired that M&A engine with operational levers: private label expansion, small-customer outreach, and a digital push that drove more than 120% growth in digital sales through SiteOne.com in fiscal 2025. Full-year 2025 revenue reached $4.70 billion, with net income up 22.82% to $151.8 million.

A Decade Up, Five Years Sideways Here’s what a $1,000 investment would have delivered at each horizon, using split-adjusted prices through the May 4, 2026, close.

Since IPO (May 12, 2016): Total return of 370.3%, with shares moving from $26.67 to $125.43 (S&P 500 over the same window: 247.6%.) 5-Year Return: −35.18%, from $193.50 to $125.43 (S&P 500: +72.7%.) 1-Year Return: +2.96%, from $121.82 to $125.43 (S&P 500: +26.69%.) The shape of those returns matters. SiteOne surged higher into 2021’s pandemic-era housing boom, then gave most of it back as new residential construction and repair-and-upgrade demand cooled. SiteOne pays no dividend, so the entire return is price. Anyone who bought near the 2021 peak is still underwater. Anyone who held from IPO crushed the S&P 500, even after the latest drawdown.

The Takeaway The case for investing $1,000 in SiteOne today begins with a belief that housing starts will keep climbing from the 1.50 million annualized print in March 2026 and management converts its acquisition pipeline into the $425 million to $455 million adjusted EBITDA guidance. The bull case is straightforward: dominant national scale in a fragmented market, 90 basis points of Q1 gross margin expansion despite weather chaos, and $20.0 million in Q1 buybacks signaling capital-allocation discipline.

The case against is strengthened if the macro backdrop keeps deteriorating. Q1 2026 was ugly: revenue of $940.1 million missed estimates by 4.2%, EPS came in at −$0.60 against a −$0.33 estimate, and consumer sentiment registered 53.3, in recessionary territory. A trailing P/E of 37 on a cyclical distributor with negative quarterly EPS is not cheap.

The outlook remains cautiously constructive. While the structural growth thesis remains intact, a clearer inflection in demand is necessary before establishing a position. SiteOne remains a priority watchlist name pending more definitive evidence of a recovery in market volume.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. “I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins. Our growth outlook, combined with the progress made on value-creation initiatives.

Henry Schein (HSIC - Free Report) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +10.30%. A quarter ago, it was expected that this health care products maker would post earnings of $1.3 per share when it actually produced earnings of $1.34, delivering a surprise of +3.08%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Henry Schein, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $3.37 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.15%. This compares to year-ago revenues of $3.17 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Henry Schein shares have lost about 4.7% since the beginning of the year versus the S&P 500's gain of 5.2%.

What's Next for Henry Schein?While Henry Schein has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Henry Schein was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.19 on $3.37 billion in revenues for the coming quarter and $5.30 on $13.69 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Becton Dickinson (BDX - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This medical device manufacturer is expected to post quarterly earnings of $2.77 per share in its upcoming report, which represents a year-over-year change of -17.3%. The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level.

Becton Dickinson's revenues are expected to be $4.67 billion, down 11.5% from the year-ago quarter.

For the quarter ended March 2026, Henry Schein (HSIC - Free Report) reported revenue of $3.37 billion, up 6.3% over the same period last year. EPS came in at $1.32, compared to $1.15 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.33 billion, representing a surprise of +1.15%. The company delivered an EPS surprise of +10.3%, with the consensus EPS estimate being $1.20.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Henry Schein performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- International Distribution and Value-Added Services- Dental: $900 million versus the four-analyst average estimate of $857.3 million. The reported number represents a year-over-year change of +12.8%.Geographic Revenue- International Distribution and Value-Added Services- Medical: $30 million compared to the $26.86 million average estimate based on four analysts. The reported number represents a change of +20% year over year.Geographic Revenue- U.S. Distribution and Value-Added Services: $1.91 billion compared to the $1.91 billion average estimate based on four analysts.Geographic Revenue- U.S. Distribution and Value-Added Services- Dental- Merchandise: $624 million versus $604.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.Net Sales- Global Specialty Products: $397 million versus $398.74 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change.Net Sales- Global Technology: $173 million versus $173.27 million estimated by six analysts on average.Net Sales- Global Distribution and Value-Added Services: $2.84 billion compared to the $2.8 billion average estimate based on six analysts.Net Sales- Eliminations: $-41 million versus the six-analyst average estimate of $-40.66 million. The reported number represents a year-over-year change of +10.8%.Net Sales- Global Distribution and Value-Added Services- Global Dental: $1.77 billion versus the four-analyst average estimate of $1.7 billion.Net Sales- Global Distribution and Value-Added Services- Global Medical: $1.07 billion compared to the $1.09 billion average estimate based on four analysts.Geographic Revenue- International Distribution and Value-Added Services: $930 million compared to the $884.16 million average estimate based on four analysts.Net Sales- Global Distribution and Value-Added Services- Global Dental- Global Equipment: $417 million versus $411.03 million estimated by four analysts on average.View all Key Company Metrics for Henry Schein here>>>

Shares of Henry Schein have returned -3.8% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Henry Schein (HSIC - Free Report) Melville, NY-headquartered Henry Schein Inc. is a leading distributor of health care products and services across the globe. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein operates in 34 countries.

HSIC is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 14.04; value investors should take notice.

One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.00 to $5.30 per share. HSIC also boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, HSIC should be on investors' short list.

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.

Henry Schein NASDAQ: HSIC executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.

Speaking at a Bank of America healthcare technology and distribution event, Chief Executive Officer Fred Lowery, who has been in the CEO role for about two months, said the company had a “good Q1,” citing healthy growth in dental, strong growth in technology and distribution, and margin expansion during the quarter. Lowery said medical was softer, but that excluding flu-related impacts, underlying performance was “pretty good,” with mid-single-digit growth.

Lowery said Henry Schein recommitted to delivering a $125 million net run-rate value creation benefit by the end of the year and $200 million over the next several years. He also said the company reconfirmed its 2026 guidance.

Get Henry Schein alerts:

CEO Focuses on Customers, AI and Commercial Alignment Lowery said his first 100 days are centered on learning the business through meetings with customers, suppliers and employees, whom the company refers to as “Team Schein” members. He said he is assessing current projects and evaluating where the company should invest for future growth.

One area of focus is artificial intelligence, which Lowery said could help accelerate new product development and improve capabilities brought to market, particularly in Henry Schein’s technology business. He also pointed to commercial alignment as an opportunity, saying the company wants to present customers with a broader value proposition across multiple parts of Henry Schein.

Lowery said the company is working to shift its customer message from helping customers save money to helping them “make more money,” grow faster and operate more productively.

Operational Savings Expected to Build in Second Half Chief Financial Officer Ron South said the $125 million target represents the expected net run-rate operating income improvement as the company enters 2027. He said Henry Schein expects some benefit in 2026, with savings more weighted toward the second half of the year.

South said the timing is largely due to general and administrative initiatives, which require planning and structural changes in how the company supports the business. He said the goal is to create a scalable structure that can support growth without adding significant incremental cost.

Gross profit optimization is expected to contribute sooner, South said, with some benefit already seen in the first quarter. He cited dynamic pricing as one example, adding that it does not only mean increasing prices but can also include lowering prices in areas where Henry Schein wants to be more competitive.

Dental Momentum Continues; Medical Growth Excluding Diagnostics South said dental momentum seen in April continued into May. He said achieving the company’s desired dental growth requires taking market share, which includes retaining current customers and reducing churn.

In medical, South said point-of-care diagnostic kit sales weighed on first-quarter growth because demand for those products is tied to the respiratory illness season, including flu and RSV. Excluding that category, he said the medical business grew in the mid-single digits.

South said the diagnostic kit category is typically more important in the fourth and first quarters, so he expects less impact in the middle of the year. He also highlighted Henry Schein’s home solutions business, which he said now accounts for more than 10% of medical revenue, with a run rate of more than $400 million. He said the business grows faster and has better margins than core medical.

Margins Supported by Private Label and Pricing Tools South said gross margin improvement in distribution reflected early benefits from gross profit optimization, stability in glove pricing and faster growth in company-owned brands, or private label products. He said those products carry better gross margins than the overall portfolio and that he believes the margin level can be sustainable.

Asked about exposure to oil-linked inputs, South said some product categories may be affected by petroleum-based materials. He said Henry Schein can consider price increases where needed, redirect customers to similar products with less cost pressure, or use private label alternatives where available. He compared the approach to how the company managed tariff volatility last year.

South also noted that oil prices can affect freight costs. He said the company is working with customers to explain any fuel surcharges where needed and believes its approach remains in line with the market.

DSO, Specialty and M&A Opportunities Lowery said he has met with many of Henry Schein’s largest dental service organization customers and some smaller DSOs. He said those customers see value in Henry Schein and believe there is more the parties can do together.

Lowery identified corporate brands and practice management software as areas of opportunity with DSOs. He said the company expects to expand corporate brand share with DSOs over multiple years rather than through a quick, one-time shift.

In specialty, South said the segment grew about 8%, while local internal growth was 1.7%, a rate the company expects to improve as the year progresses. In the U.S. implant market, he said value implants continue to grow faster than premium implants, both in the market and in Henry Schein’s portfolio. He said the company’s acquisition of the S.I.N. U.S. distributor gives it greater control over that portfolio.

South said Henry Schein will remain disciplined on mergers and acquisitions, with a focus on higher-growth, higher-margin areas such as specialty products, technology and value-added services. He said home solutions also remains an area for potential fold-in acquisitions because it is growing faster and has higher margins than the company’s core medical business.

Lowery said he will measure success over the next year by whether Henry Schein delivers on its 2026 guidance, achieves its value creation commitments and develops a clearer line of sight toward accelerating growth more profitably as an extension of its BOLD+1 Strategy.

About Henry Schein NASDAQ: HSICHenry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Henry Schein Right Now?Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Henry Schein (HSIC - Free Report) Melville, NY-headquartered Henry Schein Inc. is a solutions company for health care professionals that combines distribution, technology, and value-added services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein operates in 34 countries and offers a comprehensive selection of more than 300,000 branded products.

HSIC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 13.83; value investors should take notice.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $5.31 per share. HSIC also boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, HSIC should be on investors' short list.

Key Takeaways HSIC benefits from a broad dental and medical distribution network and revenue growth driven by acquisitions.HSIC's growth is supported by digital dentistry adoption, AWS collaboration and distribution agreements.HSIC faces leverage and macroeconomic pressures, including debt load, inflation and cost volatility. Henry Schein, Inc. (HSIC - Free Report) is well-poised to grow in the coming quarters due to its scale in dental and medical distribution. The company’s revenue expansion has been consistently supported by niche acquisitions and partnerships. The rising adoption of digital imaging and chairside workflows backs Henry Schein’s global digital dentistry push and can drive continued attachment of equipment, service and supplies. Yet, headwinds from macroeconomic factors and a debt-heavy balance sheet raise concerns. 

Over the past year, this Zacks Rank #3 (Hold) stock has climbed 5.2% compared with the 3.3% growth of the industry and the 31.4% rise of the S&P 500 composite.

The leading distributor of healthcare products and services has a market capitalization of $8.42 billion. The company’s earnings are expected to rise 7% in 2026 compared with the industry’s 5.1% growth. In the trailing four quarters, the company delivered an average earnings surprise of 3.74%.

Let’s delve deeper.

HSIC’s TailwindsWidespread Network and Channel Mix: Henry Schein’s distribution footprint supports broad customer coverage and operating efficiency across dental and medical markets. Apart from North America, the company has a presence in Australia and New Zealand, as well as in emerging nations like China, Brazil, Israel, the Czech Republic and Poland. In 2025, it also expanded its wide range of solutions and services in the Hawaiian Islands through the acquisition of R. Weinstein, Inc. In the first quarter of 2026, Global Distribution and Value-Added Services generated $2.84 billion of net sales, up 2.5% year over year. Management reaffirmed 2026 total sales growth guidance of about 3% to 5%, which keeps the focus on leveraging scale, service levels and supplier relationships to gain share over time.

Image Source: Zacks Investment Research

Expansion Through Acquisitions, Partnerships and Value Creation: Henry Schein’s acquisition strategy is to pursue targets that add product capabilities and expand its access to faster-growing categories. In first-quarter 2026, acquisitions contributed 0.7% to total net sales growth. The company also acquired a controlling interest in its S.I.N. distributor in the United States to enhance its position in the value implant market and support its business integration strategy.

In 2025, Henry Schein expanded its agreement with vVARDIS to become the exclusive U.S. distributor of the drill-free Curodont Repair Fluoride Plus product across all dental market segments. The company has also been investing in technology partnerships, including its collaboration with Amazon Web Services to integrate generative AI across the Henry Schein One ecosystem, and launched LinkIt to improve digital workflow connectivity for Dentrix users.
Alongside these growth initiatives, management is advancing its value creation program, recording $12 million of restructuring expense in first-quarter 2026 as the company executes on its operational plan.

Dental Business Trends Seem Favorable for the Long Term: As dentistry adopts digital imaging and chairside workflows, Henry Schein’s efforts to expand digital dentistry globally can support continued attachment of equipment, service and supplies. The company sells its consumable merchandise and manufactures specialty products in implants, orthodontics and endodontics, which helps it address a wider range of practice needs.

In the first quarter of 2026, Global Dental’s net sales were $1.77 billion, up 3.2% year over year. Management noted that dental practices and DSOs continued to invest in equipment and that the backlog in traditional equipment remained healthy. Dental procedure volumes held steady despite higher merchandise prices, which is consistent with a stable demand environment. In Specialty Products, value implant systems grew in the high single-digits, with improved growth projected in the segment as the year progresses. Premium implants were supported by clinical engagement and new product launches.

What Ails HSIC Stock?Weak Solvency: Henry Schein ended the first quarter of 2026 with cash and cash equivalents of $138 million, down from $156 million at the end of fourth-quarter 2025. The balance sheet remains levered, with current debt of $1.08 billion and long-term debt of $2.33 billion. At quarter-end, the debt-to-capital ratio was 37.6%, while times interest earned was 4.5X.

Macroeconomic Challenges: The company remains exposed to swings in inflation, foreign exchange and freight costs that can affect demand and profitability. In first-quarter 2026, adjusted operating margin increased 28 basis points year over year to 7.53% on gross margin expansion and mix, yet cash flow was seasonally negative. Henry Schein’s 2026 guidance assumes stable dental and medical end markets and that tariff changes and higher oil prices can be mitigated, but it also signals that product pricing and shipping costs are moving parts.

HSIC Stock Estimate TrendThe Zacks Consensus Estimate for HSIC’s 2026 earnings per share (EPS) has moved to $5.32 from $5.30 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $13.72 billion. This suggests a 4.1% rise from the year-ago reported number.

 Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 40.2% against the industry’s 7.7% fall over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 10.3% for fiscal 2026 compared with the industry’s 9.5% growth. Shares of the company have dropped 11% compared with the industry’s 3.3% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.7% against the industry’s negative 15.7% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 19.9% against the industry’s 7.6% decline over the past year.

Henry Schein NASDAQ: HSIC executives said the company is on track with its 2026 commitments and value-creation plan, while pointing to continued momentum in the U.S. dental market despite broader concerns about consumer confidence.

Speaking at a Stifel dental track event moderated by Stifel Managing Director Jon Block, Fred Lowery, who became Henry Schein’s chief executive officer in March, said his first roughly 100 days have been focused on “listening and learning” and organizing priorities into three areas: delivering on commitments, simplifying the business and scaling for growth.

Lowery said Henry Schein remains on track to deliver on its 2026 guidance and previously outlined value-creation initiatives. He also said the company has opportunities to simplify a decentralized business structure, including joint ventures and aspects of its commercial approach, while building on its technology, own-brand and distribution capabilities.

Get Henry Schein alerts:

Dental Demand Remains Steady Lowery said the dental market has remained relatively steady because a large portion of dental demand is tied less to consumer sentiment and more to employment and insurance coverage.

He described two major groups of patients: those who visit the dentist every six months, often with employer-provided insurance, and those who delay treatment until pain, discomfort or visible issues require care. Lowery said a smaller portion of the market is more discretionary, including cosmetic procedures.

“As long as people are working at a reasonable rate, and unemployment rates have been pretty steady, I think that bodes well for the market overall,” Lowery said.

Ron South, Henry Schein’s senior vice president and chief financial officer, said the company saw dental momentum improve through the first quarter, with February better than January and March better than February. He said that momentum continued into April and through the first part of May.

South said Henry Schein has not yet seen a direct correlation between recent weaker consumer confidence measures and its dental business. He attributed the company’s improvement in dental to momentum that began in the third quarter of last year, including promotional activity in mid-2025 that helped the company gain market share in the second half of that year.

South said Henry Schein has moved “a little more on offense” and is seeing benefits from hiring experienced sales representatives and emphasizing its role as a solutions provider rather than only a product provider.

Medical and International Trends Lowery said Henry Schein’s medical business faced pressure in the first quarter from diagnostic test kits tied to respiratory illness, primarily flu. Excluding that headwind, he said the underlying medical business grew at a mid-single-digit rate, and that trend has continued into the second quarter.

Lowery also highlighted strong growth in the company’s home solutions business.

On international markets, South said Germany has remained a steady market for Henry Schein in core dental and specialty. He also cited Canada as a strong business that has managed competitive challenges well.

Revenue Growth and New Products South said first-quarter overall revenue growth benefited by about three points from foreign exchange, a benefit he expects to diminish as the year progresses. He said the company expects to improve its internal growth rate after first-quarter headwinds from point-of-care diagnostic kits in medical and timing in the specialty business.

Lowery said Henry Schein continues to expect suppliers to invest in new products and views its distribution network as an attractive launch platform. He pointed to Curodont, which he said is being launched exclusively through Henry Schein’s distribution network, as an important product in the company’s portfolio.

Lowery also said Henry Schein is accelerating new capabilities in its technology business, including through internal artificial intelligence development and partnerships that can plug into its clinical workflow and practice management systems. He said investors should expect a “steady drumbeat” of new products and capabilities in technology, along with continued product launches in specialty products.

In implants, Lowery said Henry Schein became the majority owner of the S.I.N. U.S. distribution business in the first quarter. He described S.I.N. as a value implant business operating in a part of the U.S. market where growth is strong.

Value-Creation Plan Lowery said Henry Schein’s value-creation plan is broader than cost reduction and includes gross profit improvement and operating efficiency. He said the company is investing in analytics, tools and personnel to improve pricing visibility and make more targeted decisions on where to raise or lower prices.

He said Henry Schein is also focused on expanding its own brands and building shared-service capabilities for back-office functions with an outsourced partner. Lowery added that the company is developing systems, processes and personnel to better leverage its scale in indirect sourcing.

Lowery said the company has line of sight to a $125 million net run-rate operating income improvement by the end of 2026 and expects to deliver up to $200 million over the next few years.

South said the $125 million run-rate target supports the possibility of double-digit earnings growth in 2027, though he said it is too early to provide 2027 guidance.

Portfolio, Equipment and Capital Allocation Lowery said Henry Schein is comfortable with the current perimeter of its business, including the medical segment. He said the medical and dental businesses are integrated from a supply chain standpoint, with about 30% of SKUs overlapping between the two.

On dental equipment, South said Henry Schein’s U.S. equipment mix remains roughly two-thirds traditional equipment and one-third digital equipment. He said lower average selling prices for intraoral scanners may encourage more dental practices to adopt digital technology, potentially creating future opportunities for additional digital equipment sales.

Lowery said Henry Schein remains committed to a balanced and disciplined capital allocation strategy. He said share repurchases have been prioritized recently and are likely to remain a priority in the near term because he believes the stock is undervalued.

Lowery said the company also wants to maintain flexibility for strategic investments and would approach mergers and acquisitions in a disciplined way, focusing on assets that support customers, drive future organic growth, expand margins and generate appropriate shareholder returns.

About Henry Schein NASDAQ: HSICHenry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Henry Schein Right Now?Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

© Chaay_Tee / iStock via Getty Images

Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The “Buy the Dip” traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to hit bids that have moved higher. The song remains the same: the war with Iran, inflation (which saw the Consumer Price Index jump to 4.2%), yields moving higher, and rotation out of the AI/Datacenter trade continue to keep the sellers coming back for more. With the gigantic SpaceX IPO set to trade on Friday, some of the selling could be to raise cash to pay for allocations, which should be big for institutions, but the reality is we could be on the edge of a much bigger sell-off. The Nasdaq was the biggest loser on the day, falling 1.98% to close at 25,169, while the Dow Jones Industrial Average was not far behind, ending the session at 49,918, down 1.87%. The S&P 500 closed at 7,266, down 1.62%, and the Russell 2000 was last seen at 2,835, down 1.10%.

Treasury Bonds: Yields were higher across the Treasury curve, but the selling pressure wasn’t as severe as in equity markets. The huge CPI print, while the highest in 3 years, was expected, as that is where estimates were. Had the estimate been dramatically lower, we would have likely seen much more selling pressure. The 30-year-long bond closed the day at 5.03%, while the benchmark 10-year note finished the day at 4.55%. 

Oil and Gas: Needless to say, with the possibility of the war with Iran ratcheting up, energy prices across the board moved higher on Wednesday. When the closing bell rang, Brent Crude’s final print was recorded at $94.60, up 3.44%, while West Texas Intermediate closed the session at $90.03, up 2.07%. Natural gas tagged along for the energy ride, finishing the day at $3.19, up 1.43%.

Gold: Gold had another tough day, and the trend for the precious metal is starting to look bad, as it hit its lowest level since last November. This selling trend follows reports that China bought +10 tonnes (a tonne is a metric reference, which is higher than the US ton) of gold in May, the largest monthly addition since January 2025. This follows +8 tonnes acquired in April, marking their 3rd consecutive monthly net purchase. China has now bought gold for 19 consecutive months, the longest streak since at least 2015, when its central bank began publishing more regular data on its gold reserves. The final trade for the precious metal on Wednesday came in at $4070.30, down 4.42%, while Silver was last seen at $62.25, down 2.95%. 

Crypto: Cryptocurrencies endured a volatile Wednesday, with Bitcoin sliding to around $61,000 as the broader market grappled with a cooling AI sector and persistent institutional outflows. Although prices received an early lift from softer-than-expected U.S. inflation data, overall sentiment stayed firmly under pressure. At 8 AM EDT, Bitcoin was trading at $63,050, while Ethereum was trading at $1,665. 

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock. 

Here are some of the Best Wall Street analyst upgrades, downgrades, and initiations seen on Thursday, June 11, 2026.  

Upgrades: Black Hills (NYSE: BKH | BKH Price Prediction) was upgraded to Buy from Neutral at Bank of America, which nudged their target price to $78 from $76. The company is merging with Northwestern Energy in an all-stock deal. CME Group (NYSE: CME) was raised to Buy from Neutral by Rothschild & Co Redburn, which bumped the target price for the shares to $323 from $316. General Dynamics (NYSE: GD) was upgraded to Buy from Hold at Jefferies, which raised the price target for the Defense giant to $400 from $380. Henry Schein (NASDAQ: HSIC) was upgraded to Buy from Neutral at BTIG, with a $100 target price. Intel (NASDAQ: INTC) was double upgraded to Buy from Underperform at Bank of America, which raised the target price for the legacy chip giant to $135 from $96. Downgrades: Chewy (NYSE: CHWY) was downgraded to Neutral from Buy at MoffettNathanson, without a price target. J.Jill (NYSE: JILL) was cut to Market Perform from Outperform at William Blair, without a price target. MarketAxess Holdings (NASDAQ: MKTX) was cut to Neutral from Buy at Rothschild & Co Redburn, which slashed the price target for the shares to $134 from $189. Procept Biorobotics (NASDAQ: PRCT) was downgraded to Market Perform from Outperform at Leerink, which cut the target price for the stock to $29 from $31. Initiations: Callaway Golf (NYSE: CALY) was assumed in coverage with a Neutral rating at Goldman Sachs, which has set a $17 target price. Danaher (NYSE: DHR) was initiated with a Neutral rating at Piper Sandler, with a $200 target price objective. SpaceX (NASDAQ: SPCX) was started with no rating, but a $165 target price at New Street. Oppenheimer initiated coverage of the shares with an Outperform rating and a $190 target price. The massive IPO will start trading on Friday at $135. Rocket Lab USA (NASDAQ: RKLB) was started with a Neutral rating at KGI Securities, with a $105 target price. Toast (NYSE: TOST) was assumed with an Overweight rating at Piper Sandler, with a $32 target price.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful multi-year execution path can plausibly deliver triple-digit returns. The $50 ceiling is the filter; the AI flywheel is the thesis.

With that in mind, here are seven healthcare AI stocks trading under $50 where the bull case is grounded in product, partnership, or platform data, not hype.

Tempus AI Tempus AI (NASDAQ: TEM | TEM Price Prediction) pairs genomic diagnostics with a massive healthcare data library that pharma partners license for AI-driven drug discovery. At around $43.93, shares are down 25.6% year to date and are well below the $67.20 analyst target price, with 10 Buy or Strong Buy ratings against one Sell.

Q4 2025 revenue grew 83% year over year to $367.21 million, adjusted EBITDA flipped positive at $12.89 million, and 2026 guidance calls for $1.59 billion in revenue and roughly $65 million in adjusted EBITDA. CEO Eric Lefkofsky said “network effects from our investments in AI continue to compound,” backed by deepening partnerships with Gilead, Merck, and Daiichi Sankyo. The risk is that an accumulated deficit of $2.4 billion, heavy stock-based comp, and the $460 million in convertible notes priced in May 2026 add dilution and execution risk. Still, the data flywheel keeps spinning.

Hims & Hers Health Hims & Hers Health (NYSE: HIMS) runs a direct-to-consumer telehealth platform that uses AI to personalize care across weight loss, dermatology, mental health, and sexual wellness. At about $25.05 a share, the stock is down 57.2% over one year, with a forward P/E near 48x.

FY2026 guidance was raised to $2.80 billion to $3.00 billion in revenue and $275 million to $350 million in adjusted EBITDA, and management is targeting $6.5 billion in revenue and $1.3 billion adjusted EBITDA by 2030. International revenue surged 969% to $78.19 million, and a $250 million buyback was authorized. CEO Andrew Dudum called 2026 “a defining year.” The bull case is based on subscriber growth, the Novo Nordisk branded GLP-1 partnership, and international scaling. Notably, Q1 2026 EPS missed consensus estimates by 396.74%, U.S. revenue declined, and ongoing FDA and securities lawsuits around compounded GLP-1s remain unresolved.

Doximity Doximity (NYSE: DOCS) operates the dominant professional network for U.S. physicians, now layered with Doximity GPT and clinical AI workflow tools. Trading at around $18.97, the stock is down 57.2% year to date, with a PEG ratio of 0.715 and a forward P/E near 16x.

The platform now reaches 800,000+ active prescribers, with nearly half using clinical AI and prompts per user nearly doubling between January and April 2026. FY2026 generated $644.86 million in revenue, $196.05 million in net income, and $317.50 million in free cash flow, and the company repurchased $431.7 million of stock. The triple-digit upside thesis depends on AI engagement converting into pharma ad pricing power. The risk here is that FY2027 revenue guidance of $664 million to $676 million implies meaningful growth deceleration, and stock-based comp doubled. The cash generation cushions the multi-year story.

Nurix Therapeutics Nurix Therapeutics (NASDAQ: NRIX) applies an AI and computational platform to targeted protein degradation, a next-generation drug modality. At about $15.86, shares are well below the $30.18 analyst target, with 17 Buy or Strong Buy ratings and zero Holds or Sells.

Lead asset bexobrutideg, a BTK degrader, is enrolling the Phase 2 DAYBreak CLL-201 study, with Phase 3 DAYBreak CLL-306 set to start mid-2026 and an IND submission planned in autoimmune indications. CEO Arthur Sands has positioned bex as a “potential best-in-class” CLL therapy. Active collaborations with Gilead, Sanofi, and Pfizer carry 50/50 U.S. profit-share opt-ins, and $540.73 million in cash may fund the runway through 2027 readouts. However, Q1 revenue collapsed 66.1% year over year as the Sanofi initial research term expired, and clinical trials can fail at any stage.

Schrödinger Schrodinger (NASDAQ: SDGR) combines physics-based simulation with AI in a drug discovery platform used by most major biopharma R&D groups. At around $11.95, the stock is down 33.2% year to date, with analysts targeting $20.88.

FY2026 guidance calls for ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million, with the Bunsen agentic AI co-scientist launching in summer 2026. Lilly’s pending acquisition of co-founded Ajax Therapeutics for up to $2.3 billion validates the ecosystem; Schrodinger holds a 5.8% stake. CEO Ramy Farid said, “the biopharmaceutical funding environment is improving,” which matters since software revenue is mid-transition. Yet operating cash flow swung to negative $14.83 million from positive $144 million year over year, and cash burn is meaningful. If Bunsen lands, the multi-year setup is compelling.

Phreesia Phreesia (NYSE: PHR) sells AI-enabled patient intake and provider workflow software to thousands of healthcare practices. At about $8.77, the stock is down 65.9% over one year, with an analyst target of $15.39 and a forward P/E near 18x.

FY2026 delivered Phreesia’s first-ever positive GAAP net income year, with adjusted EBITDA above $100 million and free cash flow over $50 million. Q4 free cash flow set a record at $28.5 million, up 210%. CEO Chaim Indig said the “underlying platform is stronger than it has ever been.” The bull case is based on AI-driven margin expansion plus a depressed share price. Risk: FY2027 revenue guidance was cut to $510 million to $520 million on pharma manufacturer pullback in vaccines and GLP-1 categories, sending shares down roughly 25%. Profitability is durable; growth visibility is not.

AbCellera Biologics AbCellera Biologics (NASDAQ: ABCL) runs an AI and machine-learning antibody discovery platform, now also advancing its own internal pipeline. At around $4.09, the stock is up 102.5% over one year but well below the $10.14 analyst target, implying meaningful upside.

Q1 revenue grew 96.3% year over year to $8.31 million and EPS beat by 29%. Lead asset ABCL635, a non-hormonal antibody for vasomotor symptoms, posted positive Phase 1 interim data with about a 24-day half-life supporting monthly dosing; the addressable market is over $6 billion, with 12 million U.S. women suffering moderate-to-severe VMS. CEO Carl Hansen described the upcoming Q3 2026 Phase 2 readout as “highly de-risking,” followed by an ABCL575 Phase 1 readout in Q4 2026. With around $655 million in available liquidity, the balance sheet is strong. The risks are pre-revenue burn and binary trial outcomes.

The Takeaway A low share price by itself is never a reason to buy or avoid a stock. Each of these names carries real volatility, ongoing losses or dilution exposure, and execution risk that could materially change the thesis. Treat this list as a research starting point, dig into the latest filings, and size positions accordingly before acting.

Dr Martens PLC (LSE:DOCS) shares stomped 6.5% higher to 68.5p as the bookmaker returned to profit growth last year, thanks to reduced discounting as part of a turnaround centred on higher-quality sales.

The FTSE 250-listed group reported an adjusted pre-tax profit of £55 million in the year to 29 March, up 61% on the year before, while revenue fell 2.9% to £764.9 million.

Gross margin increased to 66.2% from 65.0% as the company cut clearance activity across both its own stores and wholesale operations.

Shoes were the "current growth engine", with sales up 19%, while boots are "showing signs of stabilisation" as sales fell 8%, and bags remained "a long-term growth opportunity, with good early results" as sales grew 15%.

Group net debt excluding leases fell to £69.7 million from £94.1 million. The dividend was maintained at 2.55p.

The company has spent the past two years stabilising the business after weaker demand and excess inventory hurt profits, particularly in the US.

Management, led by chief executive Ije Nwokorie, is now shifting from a “channel-led” model to a “consumer-first” strategy, with greater focus on full-price sales, selective retail investment and wholesale partnerships.

Nwokorie, a former senior director in Apple's retail arm, said the group was now moving into the “scale phase” of the strategy in the new 2027 financial year, with a focus on retail store estate rather than opening new sites.

“There is still work to do in pivoting the business,” he said, adding that demand for the brand continued to strengthen, with growing interest from collaborators and wholesale partners.

The company said it expected “further strong” profit growth this year despite geopolitical uncertainty and weaker consumer confidence in some markets.

Analyst John Stevenson at Peel Hunt said PBT was ahead of his £52.3 million forecast, but also includes a restatement of the US tariff amount of circa £4 million, which leaves underlying PBT "broadly in line with our forecasts if we strip this out".

He noted "good progress" around the group, with US direct-to-consumer sales up 14%, wholesale back in growth and a "strong order book" for autumn/winter.

"There is a wide range to consensus, at £61-71 million FY27 PBT, with numbers likely to move towards the lower end, in our view, reflecting the challenging trading in EMEA."

  ** UPDATE: Adds share price and broker comments **

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins." 

On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.” 

On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins." 

On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.” 

On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

If you currently own Doximity stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm PR Newswire

LOS ANGELES, June 8, 2026

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Doximity revealed its Q4 and full year 2026 financial results on May 13, 2026. The Company fell short of consensus estimates for full year revenue. The Company's CEO warned that increased investment in AI will "weigh on near-term margins." Based on this news, shares of Doximity fell by 23% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/docs-investors-have-opportunity-to-join-doximity-inc-fraud-investigation-with-the-schall-law-firm-302793532.html

SOURCE The Schall Law Firm

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results.  Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million.  Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins." 

On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP